Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study

BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF...

Descripción completa

Detalles Bibliográficos
Autores principales: Korten, Insa, Kieninger, Elisabeth, Krueger, Linn, Bullo, Marina, Flück, Christa E., Latzin, Philipp, Casaulta, Carmen, Boettcher, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070552/
https://www.ncbi.nlm.nih.gov/pubmed/35529332
http://dx.doi.org/10.3389/fped.2022.852551
_version_ 1784700665064325120
author Korten, Insa
Kieninger, Elisabeth
Krueger, Linn
Bullo, Marina
Flück, Christa E.
Latzin, Philipp
Casaulta, Carmen
Boettcher, Claudia
author_facet Korten, Insa
Kieninger, Elisabeth
Krueger, Linn
Bullo, Marina
Flück, Christa E.
Latzin, Philipp
Casaulta, Carmen
Boettcher, Claudia
author_sort Korten, Insa
collection PubMed
description BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4–6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment. RESULTS: OGTT categories improved after initiating ELX/TEZ/IVA therapy (p = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min (p < 0.05), whereas fasting glucose and CGM measures did not change. CONCLUSION: Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD.
format Online
Article
Text
id pubmed-9070552
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90705522022-05-05 Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study Korten, Insa Kieninger, Elisabeth Krueger, Linn Bullo, Marina Flück, Christa E. Latzin, Philipp Casaulta, Carmen Boettcher, Claudia Front Pediatr Pediatrics BACKGROUND: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance. METHODS: Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4–6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment. RESULTS: OGTT categories improved after initiating ELX/TEZ/IVA therapy (p = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min (p < 0.05), whereas fasting glucose and CGM measures did not change. CONCLUSION: Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9070552/ /pubmed/35529332 http://dx.doi.org/10.3389/fped.2022.852551 Text en Copyright © 2022 Korten, Kieninger, Krueger, Bullo, Flück, Latzin, Casaulta and Boettcher. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Korten, Insa
Kieninger, Elisabeth
Krueger, Linn
Bullo, Marina
Flück, Christa E.
Latzin, Philipp
Casaulta, Carmen
Boettcher, Claudia
Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title_full Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title_fullStr Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title_full_unstemmed Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title_short Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study
title_sort short-term effects of elexacaftor/tezacaftor/ivacaftor combination on glucose tolerance in young people with cystic fibrosis—an observational pilot study
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070552/
https://www.ncbi.nlm.nih.gov/pubmed/35529332
http://dx.doi.org/10.3389/fped.2022.852551
work_keys_str_mv AT korteninsa shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT kieningerelisabeth shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT kruegerlinn shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT bullomarina shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT fluckchristae shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT latzinphilipp shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT casaultacarmen shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy
AT boettcherclaudia shorttermeffectsofelexacaftortezacaftorivacaftorcombinationonglucosetoleranceinyoungpeoplewithcysticfibrosisanobservationalpilotstudy